Bortezomib improves adoptive T cell therapy by sensitizing cancer cells to FasL cytotoxicity

Cancer immunotherapy shows great promise but many patients fail to show objective responses, including in cancers that can respond well such as melanoma and renal adenocarcinoma. The proteasome inhibitor bortezomib sensitizes solid tumors to apoptosis in response to TNF-family death ligands. Since T...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Shanker, Anil, Pellom, Samuel T, Dudimah, Duafalia F, Thounaojam, Menaka C, de Kluyver, Rachel L, Brooks, Alan D, Yagita, Hideo, McVicar, Daniel W, Murphy, William J, Longo, Dan L, Sayers, Thomas J
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4681610/
https://ncbi.nlm.nih.gov/pubmed/26494122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-0794
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados